Barcelona snapshots

Prof. Christoph U. Correll

Christoph U. Correll psychiatrist USA Controversias Psiquiatry Barcelona
Hofstra University, USA   &   Charité - Universitätsmedizin Berlin, Germany
Talk Cognitive symptoms in the recovery of psychosis
Date Friday, April 20th, 2018
Time 15:15 to 16:00
Table Complexities in Psychiatry: psychosis and bipolar disorders
Chairman Table: Models to explain the complexity
Date Thursday, April 19th, 2018
Time 16:00 to 20:00

BIOGRAPHY

Christoph Correll, is Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA, as well as head of the department of child and adolescent psychiatry at the Charité University, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Professor Correll’s research and clinical work focus on the identification, characterisation and treatment of adults and youth with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology, comparative effectiveness, and the risk–benefit evaluation of psychotropic medications.

Professor Correll has authored or co-authored over 500 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 30 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters in as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.

ABSTRACT

Despite decades of research and the relevance of cognitive symptoms for functional outcomes and subjective well-being in patients with schizophrenia-spectrum disorders, attention has traditionally been focused on the management of positive symptoms. Since currently available antipsychotic medications predominantly treat hallucinations, delusions, disorganized thoughts and behavior and related agitation/aggression, attention has traditionally been focused on managing positive symptoms. However, clinically relevant cognitive impairment is prevalent in schizophrenia, affecting the majority of people with schizophrenia. Moreover, cognitive symptoms are closely related to functional outcomes contributing substantially to the overall illness burden of schizophrenia. In fact, for clinicians, cognitive dysfunction generally represents a "black box" that overshadows successful attempts at reintegrating patients with schizophrenia in functional social and educational/work roles. Therefore, approaches to describe, measure and manage cognitive deficits are relevant. This presentation summarizes the phenomenology, prevalence, assessment, clinical relevance for recovery and treatment approaches with regards to cognitive symptoms in patients with schizophrenia. Currently, no approved treatments targeting cognitive symptomatology in schizophrenia are available. It is hoped that progress in the understanding of the neurobiology and management of this complex and underappreciated symptom domain of schizophrenia will help develop effective strategies in the future. However, until this goal is achieved, clinicians should avoid therapeutic nihilism. Rather, the severity and impact of negative symptoms should be determined and monitored. Further, psychosocial treatments have shown therapeutic benefits. Thus, cognitive remediation, social skills training and computer-assisted training programs should be offered in conjunction with antipsychotic treatment. Several non-antipsychotic augmentation strategies can be tried off-label. Treatment plans that incorporate currently available management options for cognitive symptomatology in patients with schizophrenia-spectrum disorders should be adapted over time and based on the individual's needs, aiming to enhance overall outcomes, including the ultimate goal of functional recovery.

REFERENCES

[PDF] Petronis A (2010). E,

[PDF] Petronis A (2010). E,

[PDF] Petronis A (2010). E,

[PDF] Petronis A (2010). E,